摘要
心房颤动(AF)是较为常见的一种房性心律失常,AF的发病率和年龄呈正相关。AF患者好发缺血性脑卒中,极易导致患者残疾或死亡。口服抗凝药物能够很好的预防脑栓塞和系统性栓塞,其中华法林最为经典。由于华法林的治疗范围太过狭窄;需要规律监测国际标准化比值(INR);易受食品药品影响等原因,使抗凝治疗在我国一直受限。新型口服抗凝剂(NOAC)的研发打开了抗凝治疗的新篇章,有望增加抗凝患者的治疗比例。射频消融和经皮左心耳封堵术的有效性和安全性在临床实践中得到了肯定。NOAC联合射频消融或左心耳封堵能有效降低AF患者的血栓栓塞风险,为AF的临床治疗提供更加全面以及有效的方案。
Atrial fibrillation(AF)is a common atrial arrhythmia,and the incidence of AF is positively correlated with age.Patients with AF are prone to ischemic stroke,which can easily lead to disability or death.Oral anticoagulants can prevent cerebral embolism and systemic embolism,among which warfarin is the most classic.Because the treatment range of warfarin is too narrow,the international normalized ratio(INR)needs to be monitored regularly,and anticoagulation therapy is easy to be affected by food and drugs,it has been limited in our country.The research and development of new oral anticoagulants has opened a new chapter in anticoagulant therapy,promising to increase the treatment proportion of anticoagulant patients.The efficacy and safety of radiofrequency ablation and percutaneous left atrial appendage occlusion have been confirmed in clinical practice.New oral anticoagulants(NOAC)combined with radiofrequency ablation or left atrial appendage occlusion can effectively reduce the risk of thromboembolism in patients with AF and provide a more comprehensive and effective scheme for the clinical treatment of AF.
作者
文书
王悦喜
Wen Shu;Wang Yuexi(Inner Mongolia Medical University,Hohhot 010050,China)
出处
《心脑血管病防治》
2021年第3期265-269,共5页
CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
基金
内蒙古自治区自然科学基金(2019GG162)。
关键词
非瓣膜性心房颤动
口服抗凝药
射频消融
左心耳封堵
缺血性脑卒中
Nonvalvular atrial fibrillation
Oral anticoagulants
Radiofrequency ablation
Left atrial appendage occlusion
Ischemic stroke
